Positive preclinical results in Sprint Bioscience's oncology program targeting TREX1
Sprint Bioscience today announces that previously unpublished results from the company’s DISA program targeting the protein TREX1 will be presented at the conference "Immuno-Oncology Summit Europe 2024" in London, England, 23 – 25 April 2024. The positive results from an in vivo proof-of-concept study show that treatment with the company's TREX1 inhibitors results in an improved immune response and inhibited tumor growth.
Results show that oral administration of the company’s TREX1 inhibitors reduced tumor growth in an animal model of colorectal cancer and at the same time increased the recruitment of immune cells to the tumors.
“Targeting TREX1 represents a novel approach to amplifying the immune response, with a mechanism that is different from existing approved immunotherapies. When blocking TREX1 in tumors, the body's immune response is reactivated, resulting in inhibition of tumor growth. Our data support the therapeutic hypothesis in this program, and we look forward to presenting the program to scientists and potential partners in the immuno-oncology field.” said Martin Andersson, CSO at Sprint Bioscience.
New publications show that the function of the TREX1 protein in cancer cells inhibits the immune response. This, in combination with the company's data, confirms the hypothesis that TREX1 is an interesting new target for cancer therapy.
The poster "Inhibition of TREX1 Increases Interferon Signaling and Reduces Tumor Growth In Vivo" is presented by Camilla Silvander, PhD, Director Protein Science, Sprint Bioscience.